Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement.
Targeting the signaling pathway of the immunosuppressive metabolite adenosine is an emerging approach for cancer immunotherapy. In this issue of Cancer Cell, Young et al. describe that co-inhibition of the adenosingenic pathway through blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA.
Rony
R
Dahan
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA. Electronic address: ravetch@rockefeller.edu.
Jeffrey V
JV
Ravetch
D000241:Adenosine; D006801:Humans; D007167:Immunotherapy; D043705:Receptor, Adenosine A2A; D011961:Receptors, Fc; D015398:Signal Transduction
D043705:Receptor, Adenosine A2A; D011961:Receptors, Fc; D000241:Adenosine